Kintor Pharmaceutical Limited
9939.HK
Hong Kong Stock Exchange1.82
HKD
-0.07
- -
Kintor Pharmaceutical Limited
9939.HK
(Hong Kong Stock Exchange)
Recent
price
1.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Kintor Pharmaceutical Limited (9939.HK) is a clinical-stage biopharmaceutical company that develops innovative small-molecule and biologic drugs targeting dermatology and oncology indications with substantial unmet medical needs, particularly androgen receptor-related diseases such as alopecia, acne, prostate cancer and liver cancer. Founded in 2009 and headquartered in Suzhou Industrial Park, Suzhou, China, the company offers a diverse pipeline including KX-826 (pyrilutamide), a topical androgen receptor antagonist in phase III trials for androgenetic alopecia (AGA) and acne vulgaris, now commercialized over-the-counter as Koshiné hair loss treatment generating first revenues; GT20029, a topical AR-PROTAC compound in phase II for AGA and acne; KT-939 (oximidol), a functional raw material for skin whitening and freckle-removing cosmetics launched commercially; Proxalutamide, a second-generation AR antagonist for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors; GT90001 (ALK-1 antibody), an anti-angiogenesis biologic for hepatocellular carcinoma (HCC) and solid tumors; Detorsertib (mTOR inhibitor) for breast, prostate and HCC; Hedgehog/SMO inhibitor for blood cancers; and preclinical programs in ALK-1/VEGF dual-target antibody and c-Myc inhibitors. Kintor operates primarily in China with global patent protections exceeding 110 and a GMP-compliant manufacturing facility in Suzhou spanning 20,000 square meters. Recent developments include a strategic pivot from oncology to dermatology and cosmetics amid cash constraints, with R&D spending dropping 91.7% to 78.1 million yuan in 2024 focused on core assets KX-826 and GT20029; commercialization of six over-the-counter products including Koshiné, acne cream, whitening essence and lotion via platforms like Tmall, JD.com, Douyin and Amazon, yielding 5 million yuan revenue in 2024; positive phase III enrollment completion for KX-826 AGA tincture (July 2025), phase II primary endpoint achievement for GT20029 acne gel (August 2025), long-term safety trial completion for KT-939 (September 2025), and KX-826/minoxidil combination study meeting primary endpoint (May 2025); alongside oncology trial advancements like phase II enrollment for AR-PROTAC (June 2024) while de-emphasizing higher-cost cancer pipelines.